Skip to main content
Top
Published in: Gut Pathogens 1/2019

Open Access 01-12-2019 | Antibiotic | Research

Pancreatic disease patients are at higher risk for Clostridium difficile infection compared to those with other co-morbidities

Authors: Chetana Vaishnavi, Pramod K. Gupta, Megha Sharma, Rakesh Kochhar

Published in: Gut Pathogens | Issue 1/2019

Login to get access

Abstract

Background

Surveillance of Clostridium difficile infection (CDI) in patients with underlying diseases is important because use of prophylactic antibiotics makes them prone to CDI. Epidemiology of CDI in this high-risk population is poorly understood. A study was conducted to evaluate the impact of CDI in patients with specific underlying co-morbidities.

Method

A total of 2036 patients, whose fecal samples were processed for C. difficile toxin A and B assay by ELISA formed the basis of study. Patients with underlying diseases were classified based on the organ/kind of disease as pancreatic (n = 340), renal (n = 408), hepatic (n = 245), malignant (n = 517) and miscellaneous disease (n = 526). Laboratory records of clinical and demographic details were reviewed. The association of CDI with age, gender, antibiotic receipt, clinical symptoms and underlying co-morbidities was analyzed. Variation in CDI cases based on age groups was also investigated.

Result

Clostridium difficile toxin positivity was 21.6% in general, whereas it was 30.6% in the pancreatic, 17.9% in the renal, 19.6%, in the hepatic, 21.3% in the malignancy and 20.0% in the miscellaneous disease groups. Toxin positivity was the lowest (14.8%) for female gender under renal disease and the highest (31.8%) for patients aged 40 to < 60 years, under pancreatic disease. Bloody diarrhea was a significant predictor for C. difficile toxin positivity. C. difficile toxin status irrespective to the underlying diseases was neither dependent on gender, age-groups or the number of antibiotics used. Association between patients’ gender, age and antibiotics receipt with underlying disease conditions, respective to C. difficile toxin status showed significance in relation to male gender (p < 0.05), age 40 to < 60 years (p = 0.03) and those receiving single (p = 0.09) or multiple antibiotics (p = 0.07).

Conclusion

Pancreatic disease patients are at a higher risk for developing CDI, and particularly male gender, age 40 to < 60 years and those receiving antibiotics are at significant risk.
Literature
1.
go back to reference Bartlett JG. Clinical practice. Antibiotic associated diarrhea. N Engl J Med. 2002;346(5):334–9.CrossRef Bartlett JG. Clinical practice. Antibiotic associated diarrhea. N Engl J Med. 2002;346(5):334–9.CrossRef
3.
go back to reference Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543–9.CrossRef Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543–9.CrossRef
4.
go back to reference Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175:745–8.CrossRef Dial S, Delaney JA, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006;175:745–8.CrossRef
5.
go back to reference Vaishnavi C. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol. 2009;27:291–302.CrossRef Vaishnavi C. Established and potential risk factors for Clostridium difficile infection. Indian J Med Microbiol. 2009;27:291–302.CrossRef
6.
go back to reference Vaishnavi C, Kochhar R. Inflammatory bowel disease and Clostridium difficile infection: a report from a tertiary care center of north India. J Gen Pract. 2017;5:1–6.CrossRef Vaishnavi C, Kochhar R. Inflammatory bowel disease and Clostridium difficile infection: a report from a tertiary care center of north India. J Gen Pract. 2017;5:1–6.CrossRef
7.
go back to reference Vaishnavi C, Singh M, Kapoor P, Kochhar R. Clinical and demographic profile of patients reporting for Clostridium difficile infection in a tertiary care hospital. Indian J Med Microbiol. 2015;33:326–7.CrossRef Vaishnavi C, Singh M, Kapoor P, Kochhar R. Clinical and demographic profile of patients reporting for Clostridium difficile infection in a tertiary care hospital. Indian J Med Microbiol. 2015;33:326–7.CrossRef
8.
go back to reference Owens RC. Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs. 2007;67:487–502.CrossRef Owens RC. Clostridium difficile-associated disease: changing epidemiology and implications for management. Drugs. 2007;67:487–502.CrossRef
9.
go back to reference Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6:330–6.CrossRef Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6:330–6.CrossRef
10.
go back to reference Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–83.CrossRef Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–83.CrossRef
11.
go back to reference Chopra T, Chandrasekar PH, Salimnia H, Merline J, Alangaden GJ. Current epidemiology of Clostridium difficile associated disease (CDAD) in hematopoietic stem cell transplant recipients (HSCT). In: Presented at: 45th annual meeting infectious diseases Society of America (IDSA). San Diego, CA, USA 2007; 4–7 October. Chopra T, Chandrasekar PH, Salimnia H, Merline J, Alangaden GJ. Current epidemiology of Clostridium difficile associated disease (CDAD) in hematopoietic stem cell transplant recipients (HSCT). In: Presented at: 45th annual meeting infectious diseases Society of America (IDSA). San Diego, CA, USA 2007; 4–7 October.
12.
go back to reference Murabata M, Kato H, Yano H, Ogura M, Shibayama J, Wakimoto Y, Arakawa Y, Mizokami M. Intestinal colonization and nosocomial spread of Clostridium difficile in pediatric cancer patients under long-term hospitalization. Kansenshogaku Zasshi. 2008;82(5):419–26 (Article in Japanese).CrossRef Murabata M, Kato H, Yano H, Ogura M, Shibayama J, Wakimoto Y, Arakawa Y, Mizokami M. Intestinal colonization and nosocomial spread of Clostridium difficile in pediatric cancer patients under long-term hospitalization. Kansenshogaku Zasshi. 2008;82(5):419–26 (Article in Japanese).CrossRef
13.
go back to reference Luo R, Greenberg A, Stone CD. Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. Infect Control Hosp Epidemiol. 2015;36(7):794–801.CrossRef Luo R, Greenberg A, Stone CD. Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis. Infect Control Hosp Epidemiol. 2015;36(7):794–801.CrossRef
14.
go back to reference Keven K, Basu A, Re L, Tan H, Marcos A, Fung JJ, Starzl TE, Simmons RL, Shapiro R. Clostridium difficile colitis in patients after kidney and pancreas–kidney transplantation. Transpl Infect Dis. 2004;6(1):10–4.CrossRef Keven K, Basu A, Re L, Tan H, Marcos A, Fung JJ, Starzl TE, Simmons RL, Shapiro R. Clostridium difficile colitis in patients after kidney and pancreas–kidney transplantation. Transpl Infect Dis. 2004;6(1):10–4.CrossRef
15.
go back to reference Dubberke ER, Riddle DJ. Diagnosis, treatment, and prevention of Clostridium difficile infection in solid organ transplant recipients. Am J Transplant. 2009;9(4):S35–40.CrossRef Dubberke ER, Riddle DJ. Diagnosis, treatment, and prevention of Clostridium difficile infection in solid organ transplant recipients. Am J Transplant. 2009;9(4):S35–40.CrossRef
16.
go back to reference Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, Michel JA, Dickson RC, Hughes C, Nguyen J, Chua H, Hellinger W. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int. 2007;20(10):856–66.CrossRef Albright JB, Bonatti H, Mendez J, Kramer D, Stauffer J, Hinder R, Michel JA, Dickson RC, Hughes C, Nguyen J, Chua H, Hellinger W. Early and late onset Clostridium difficile-associated colitis following liver transplantation. Transpl Int. 2007;20(10):856–66.CrossRef
17.
go back to reference Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48:568–76.CrossRef Gravel D, Miller M, Simor A, et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48:568–76.CrossRef
18.
go back to reference Musa S, Moran C, Rahman T. Clostridium difficile infection and liver disease. J Gastrointestin Liver Dis. 2010;19(3):303–10.PubMed Musa S, Moran C, Rahman T. Clostridium difficile infection and liver disease. J Gastrointestin Liver Dis. 2010;19(3):303–10.PubMed
19.
go back to reference Bajaj JS, O’Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS, On behalf of NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56(6):2328–35.CrossRef Bajaj JS, O’Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS, On behalf of NACSELD. Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American Consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology. 2012;56(6):2328–35.CrossRef
20.
go back to reference Arrich J, Sodeck GH, Sengölge G, Konnaris C, Müllner M, Laggner AN, Domanovits H. Clostridium difficile causing acute renal failure: case presentation and review. World J Gastroenterol. 2005;11(8):1245–7.CrossRef Arrich J, Sodeck GH, Sengölge G, Konnaris C, Müllner M, Laggner AN, Domanovits H. Clostridium difficile causing acute renal failure: case presentation and review. World J Gastroenterol. 2005;11(8):1245–7.CrossRef
21.
go back to reference Eui OhS, Lee SM, Lee YK, Choi SR, Choi MJ, Kim JK, Song YR, Kim SJ, Park TJ, Kim SG, Oh J, Suh JW, Yoon JW, Koo JR, Jik Kim H, Noh JW. Clostridium difficile-associated diarrhea in dialysis patients. Kidney Res Clin Pract. 2013;32:27–31.CrossRef Eui OhS, Lee SM, Lee YK, Choi SR, Choi MJ, Kim JK, Song YR, Kim SJ, Park TJ, Kim SG, Oh J, Suh JW, Yoon JW, Koo JR, Jik Kim H, Noh JW. Clostridium difficile-associated diarrhea in dialysis patients. Kidney Res Clin Pract. 2013;32:27–31.CrossRef
22.
go back to reference Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qiana Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87(11):1046–53.CrossRef Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qiana Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012;87(11):1046–53.CrossRef
23.
go back to reference Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Edmonds JP, Kaewpoowat Q, Mahaparn P, Bruminhent J, Erickson Stephen B. Chronic kidney disease and end stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis. Int J Clin Pract. 2015;69(9):998–1006.CrossRef Thongprayoon C, Cheungpasitporn W, Phatharacharukul P, Edmonds JP, Kaewpoowat Q, Mahaparn P, Bruminhent J, Erickson Stephen B. Chronic kidney disease and end stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis. Int J Clin Pract. 2015;69(9):998–1006.CrossRef
24.
go back to reference Schalk E, Bohr UR, König B, Scheinpflug K, Mohren M. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol. 2010;89(1):9–14.CrossRef Schalk E, Bohr UR, König B, Scheinpflug K, Mohren M. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol. 2010;89(1):9–14.CrossRef
25.
go back to reference Selvey LA, Slimings C, Joske DJL, Riley TV. Clostridium difficile infections amongst patients with haematological malignancies: a data linkage study. PLoS ONE. 2016;11(6):e0157839.CrossRef Selvey LA, Slimings C, Joske DJL, Riley TV. Clostridium difficile infections amongst patients with haematological malignancies: a data linkage study. PLoS ONE. 2016;11(6):e0157839.CrossRef
26.
go back to reference Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:405–9.CrossRef Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:405–9.CrossRef
27.
go back to reference Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109–13.CrossRef Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis. 1993;17(1):109–13.CrossRef
28.
go back to reference Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol. 1996;61(3):369–72.CrossRef Emoto M, Kawarabayashi T, Hachisuga MD, Eguchi F, Shirakawa K. Clostridium difficile colitis associated with cisplatin-based chemotherapy in ovarian cancer patients. Gynecol Oncol. 1996;61(3):369–72.CrossRef
29.
go back to reference Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS ONE. 2015;10(4):e0124483.CrossRef Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium difficile infection among solid organ transplant recipients: a meta-analysis of published studies. PLoS ONE. 2015;10(4):e0124483.CrossRef
30.
go back to reference Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRef Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRef
31.
go back to reference Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol. 1998;71(1):104–7.CrossRef Husain A, Aptaker L, Spriggs DR, Barakat RR. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol. 1998;71(1):104–7.CrossRef
32.
go back to reference Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I. Infection probability score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs. 2011;15:404–9.CrossRef Apostolopoulou E, Raftopoulos V, Terzis K, Elefsiniotis I. Infection probability score: a predictor of Clostridium difficile-associated disease onset in patients with haematological malignancy. Eur J Oncol Nurs. 2011;15:404–9.CrossRef
33.
go back to reference Bajaj JS, Zadvornova Y, Hafeezullah M, Saeian K. Clostridium difficile infection is associated with proton pump inhibitors in patients with cirrhosis. Hepatology. 2007;46:580A. Bajaj JS, Zadvornova Y, Hafeezullah M, Saeian K. Clostridium difficile infection is associated with proton pump inhibitors in patients with cirrhosis. Hepatology. 2007;46:580A.
34.
go back to reference Daniel A, Rapose A. The evaluation of Clostridium difficile infection (CDI) in a community hospital. J Infect Public Health. 2015;8:155–60.CrossRef Daniel A, Rapose A. The evaluation of Clostridium difficile infection (CDI) in a community hospital. J Infect Public Health. 2015;8:155–60.CrossRef
35.
go back to reference Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51:2883–7.CrossRef Jump RL, Pultz MJ, Donskey CJ. Vegetative Clostridium difficile survives in room air on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother. 2007;51:2883–7.CrossRef
36.
go back to reference Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol. 2007;51(123):1209–14.CrossRef Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol. 2007;51(123):1209–14.CrossRef
37.
go back to reference Khanna S, Pardi DS. IBD: poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(6):307–8.CrossRef Khanna S, Pardi DS. IBD: poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(6):307–8.CrossRef
38.
go back to reference Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–22.CrossRef Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–22.CrossRef
39.
go back to reference Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105:106–13.CrossRef Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol. 2010;105:106–13.CrossRef
40.
go back to reference West M, Pirenne J, Chavers B, Gillingham K, Sutherland DER, Dunn DL, Matas AJ. Clostridium difficile colitis after kidney and kidney pancreas transplantation. Clin Transplant. 1999;13:318–23.CrossRef West M, Pirenne J, Chavers B, Gillingham K, Sutherland DER, Dunn DL, Matas AJ. Clostridium difficile colitis after kidney and kidney pancreas transplantation. Clin Transplant. 1999;13:318–23.CrossRef
41.
go back to reference Han K, Ma H, An X, Su Y, Chen J, Lian Z, Zhao J, Zhu BP, Fontaine RE, Feng Z, Zeng G. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53:326–33.CrossRef Han K, Ma H, An X, Su Y, Chen J, Lian Z, Zhao J, Zhu BP, Fontaine RE, Feng Z, Zeng G. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis. 2011;53:326–33.CrossRef
Metadata
Title
Pancreatic disease patients are at higher risk for Clostridium difficile infection compared to those with other co-morbidities
Authors
Chetana Vaishnavi
Pramod K. Gupta
Megha Sharma
Rakesh Kochhar
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2019
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-019-0300-2

Other articles of this Issue 1/2019

Gut Pathogens 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.